Evidence map›Paper›PMID 28939928›Full record

SynthesisHerz2019

Acute heart failure : An unmet medical need.

A G Rigopoulos, C Bakogiannis, R de Vecchis, S Sakellaropoulos, M Ali, M Teren, M Matiakis, C Tschoepe, M Noutsias

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Herz, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

A G RigopoulosDepartment of Internal Medicine III - Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Ernst-Grube-Strasse 40, Halle (Saale), 06120, Germany.
C Bakogiannis3rd Department of Cardiology, Ippokrateio Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642, Thessaloniki, Greece.
R de VecchisCardiology Unit, Presidio Sanitario Intermedio, "Elena d'Aosta", Napoli, Italy.
S SakellaropoulosDepartment of Internal Medicine III - Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Ernst-Grube-Strasse 40, Halle (Saale), 06120, Germany.
M AliDepartment of Cardiology, Asklepios Harzklinik Goslar, Goslar, Germany.
M TerenDepartment of Internal Medicine III - Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Ernst-Grube-Strasse 40, Halle (Saale), 06120, Germany.
M MatiakisDepartment of Internal Medicine III - Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Ernst-Grube-Strasse 40, Halle (Saale), 06120, Germany.
C TschoepeDepartment of Cardiology, Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Berlin, Germany.
M NoutsiasDepartment of Internal Medicine III - Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Ernst-Grube-Strasse 40, Halle (Saale), 06120, Germany. michel.noutsias@gmx.de.ORCID http://orcid.org/0000-0002-9066-5262
University Hospital in Halle · DEAristotle University of Thessaloniki · GRAsklepios · DEBerlin-Brandenburger Centrum für Regenerative Therapien · DEPresidio Ospedaliero · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in the management of heart failure with reduced ejection fraction (HFrEF), the burden of acute heart failure (AHF) remains significant with a high morbidity and mortality that has not been improved by any treatment modality. A meta-analysis summarized the study results on the effects of tolvaptan on AHF, which failed to demonstrate an improvement in short-term and long-term mortality, length of hospital stay and reduced frequency of worsening heart failure (WHF). Similar trial results were also reported in other AHF studies, such as the ASCEND-HF and the RELAX-AHF-2 trials. In view of these inconclusive studies it is evident that improving the prognosis of AHF patients remains an unmet medical need. Further efforts should focus on organ damage protection, individualized treatment, patient benefits and standardized management programs, including immediate identification and management of cardiogenic shock and establishment of HF networks for close monitoring of AHF patients.

Indexed as

Heart FailureAcute DiseaseDisease ProgressionHumansStroke VolumeTreatment OutcomeLeft ventricular assist devicesMeta-analysisPrognosisTolvaptanTreatment

Identifiers

PMID28939928
OpenAlexW3157668543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.